Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
Contacts and Locations
No Study Results Posted
Related Studies
Fludarabine, Cyclophosphamide, Rituximab, and Stem Cell Transplant In Treating Patients With Severe Systemic Lupus Erythematosus
This study is ongoing, but not recruiting participants.
Study NCT00726518. Last updated on December 13, 2008.
Information provided by National Cancer Institute (NCI)
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Precancerous/Nonmalignant Condition
Additional conditions recognized in this trial
Lupus Erythematosus, Systemic
Precancerous Conditions
More general conditions related to this trial
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Neoplasms
Interventions listed in this trial
cyclophosphamide
filgrastim
fludarabine phosphate
methylprednisolone
rituximab
immunologic technique
laboratory biomarker analysis
Additional drug interventions recognized in this trial
Fludarabine
Fludarabine monophosphate
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
More general drug interventions related to this trial
Alkylating Agents
Anti-Inflammatory Agents
Antiemetics
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Antirheumatic Agents
Autonomic Agents
Central Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Neuroprotective Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content